Evidence map›Paper›PMID 41721457›Full record

ArticleMolecular medicine (Cambridge, Mass.)2026

Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort.

Adrián Gil-Korilis, Jorge Ergui-Arbizu, Petr Hanák, Natálie Danešová, Kristýna Tomášová, Anna Valíčková, Josef Horák, Manuel Gentiluomo, Miroslav Levý, Soňa Křivonosková and 8 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Adrián Gil-Korilis *Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0009-0001-0614-1168
Jorge Ergui-Arbizu *Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0009-0003-2583-4538
Petr Hanák *Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-2156-592X
Natálie DanešováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0009-0000-9757-2141
Kristýna TomášováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-8080-6666
Anna ValíčkováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-7101-5742
Josef HorákDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0003-2688-4273
Manuel GentiluomoDepartment of Biology, Unit of Genetics, University of Pisa, Pisa, Italy.ORCID 0000-0002-0366-9653
Miroslav LevýDepartment of Surgery, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.ORCID 0000-0003-3321-6644
Soňa KřivonoskováDepartment of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic.
Jan KrálDepartment of Internal Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.ORCID 0000-0001-6960-1013
Jiří JungwirthInstitute of Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Ludmila VodičkováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0002-8277-539X
Veronika VymetálkováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0001-6870-6788
Amaya AzquetaDepartment of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.ORCID 0000-0003-4857-9931
Daniele CampaDepartment of Biology, Unit of Genetics, University of Pisa, Pisa, Italy.ORCID 0000-0003-3220-9944
Pavel VodičkaDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic.ORCID 0000-0003-2376-1243
Soňa VodenkováDepartment of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic. sona.vodenkova@iem.cas.cz.ORCID 0000-0003-0315-5668

Funding

Charles University Czech Republic 540225Grantová Agentura České Republiky G22-05942SGrantová Agentura České Republiky GX21-04607XMinistry of Health of the Czech Republic in cooperation with the Czech Health Research Council NU22J-03-00033National Institute for Cancer Research LX22NPO5102
6 · The paper itself

Abstract

backgroundTelomere shortening and mitochondrial dysfunction are well-known independent contributors to many diseases, but emerging evidence suggests a reciprocal relationship between the two processes. The role of the so-called telomere-mitochondrial axis in colorectal cancer (CRC) remains largely unknown.

methodsThis prospective cohort study screened CRC patients who underwent surgery, from whom peripheral blood, intestinal mucosa, and tumor samples were collected. Colonoscopically confirmed cancer- and adenoma-free healthy individuals were screened as controls, from whom peripheral blood and intestinal mucosa samples were obtained. Relative mitochondrial DNA copy number (mtDNA-CN) and relative telomere length (RTL) were measured in all samples by real-time quantitative polymerase chain reaction and were further compared and correlated considering clinical data. Relative mtDNA-CN was quantified using both TaqMan probes and SYBR Green to compare both methods. Finally, multivariable analyses were conducted to investigate the association between both biomarkers and the risk of tumor recurrence and mortality.

resultsA total of 166 CRC patients and 61 healthy individuals were included in the study. In TNM stage I patients, relative mtDNA-CN and RTL were negatively correlated with each other in intestinal mucosa (ρ = -0.77, p < 0.0001), tumor tissue (ρ = -0.41, p = 0.032), and the tumor-to-intestinal mucosa ratio (ρ = -0.39, p = 0.046). However, these associations disappeared with increasing TNM stage, suggesting a dysregulation of the telomere-mitochondrial axis in advanced disease. Higher relative mtDNA-CN in blood was associated with a lower risk of disease recurrence even after adjusting for multiple covariates (HR = 0.43, 95% CI 0.20–0.97, p = 0.041), highlighting its potential use as a prognostic tool. The quantification of mtDNA-CN performed by both methods -TaqMan probes and SYBR Green- was shown to be positively correlated (p < 0.01). Relative mtDNA-CN and RTL were found to be tissue-dependent in both CRC patients and healthy controls.

conclusionsThis study provides a novel contribution to the understanding of the almost unexplored telomere-mitochondrial axis in CRC, highlighting its potential role in disease progression and prognosis.

Indexed as

Colorectal NeoplasmsMitochondriaTelomereAgedBiomarkers, TumorCase-Control StudiesDNA Copy Number VariationsDNA, MitochondrialFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProspective StudiesBiomarkers, TumorDNA, MitochondrialColorectal cancerMitochondrial DNA copy numberSYBR GreenTaqManTelomere lengthTelomere-mitochondrial axis

Identifiers

PMID41721457
PMCPMC13032530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.